At a glance
ClinicalIndex Comparison RecordPhase 2Active· 154 enrolled
Drug / intervention
Belzutifandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Belzutifan for Carcinoma, Renal Cell. Active but no longer recruiting, targeting 154 participants across 48 sites in 9 countries.
Detailed Summary
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesAustralia, Belgium, Greece, Ireland, Israel, Netherlands, Russia, United Kingdom, United States
Collaborators--
Timeline
Phase 2Active
202120222023202420252026
First PostedJul 2020
Enrollment StartSep 2020
Primary CompletionFeb 2023
TodayJul 2026
Study CompletionOct 2026
First PostedJul 28, 2020
Enrollment StartSep 13, 2020
Primary CompletionFeb 10, 2023
Study CompletionOct 4, 2026
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.9 years ago
Interventions
Belzutifandrug
Oral administration